GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT

GSA Capital Partners LLP acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 103,618 shares of the biotechnology company’s stock, valued at approximately $1,862,000. GSA Capital Partners LLP owned 0.10% of Sarepta Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of SRPT. Kestra Advisory Services LLC acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics in the 3rd quarter valued at $25,000. Ancora Advisors LLC increased its stake in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares during the period. Allworth Financial LP increased its stake in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares during the period. Finally, Larson Financial Group LLC raised its position in Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after buying an additional 851 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $18.10 on Monday. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $25.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The stock has a fifty day moving average price of $17.08 and a two-hundred day moving average price of $18.37. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -6.24, a PEG ratio of 0.24 and a beta of 0.24.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SRPT. Zacks Research upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, July 9th. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Wall Street Zen downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus target price of $25.06.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.